CTOs on the Move

Accuray

www.accuray.com

 
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative tumor treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company`s leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
  • Number of Employees: 1K-5K
  • Annual Revenue: $250-500 Million
  • www.accuray.com
  • 1310 Chesapeake Terrace
    Sunnyvale, CA USA 94089
  • Phone: 408.716.4600

Executives

Name Title Contact Details
GS Jha
Chief Information Officer Profile
Jean-Philippe Pignol
Chief Medical and Technology Officer Profile

Similar Companies

Visiting Nurse Association Ohio

Visiting Nurse Association of Ohio is the largest non-profit, community-based healthcare organization in Ohio and has been helping patients for more than 100 years. VNA of Ohio works with hospitals, doctors, community agencies and companies to provide services for patients in their homes including skilled nursing care, hospice, mental health services, rehabilitation therapies, chronic disease management and personal care assistance. With nearly 600 employees, VNA of Ohio provides high-quality, comprehensive home health and hospice care to promote optimal health, independence and dignity of those living in the communities we serve.

Renal Solutions

Renal Solutions is a Warrendale, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.

TransEngen

TransEngen is a Norwalk, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blakehurst

Blakehurst Retirement Community is a life plan community in the Baltimore area that offers a range of residential options and amenities designed to contribute to residents’ overall happiness and well-being. They specialize in senior living communities ...